NanoRepro

NanoRepro Enterprise Value

The Enterprise Value (EV) of NanoRepro (NN6.DE) as of Oct 16, 2026 is 11.40 M EUR. In the previous year, Enterprise Value (EV) was 10.06 M EUR — a change of 13.27% (higher).

Enterprise Value

11.40 MEUR

YoY

13.27%

Last updated:

Enterprise Value (EV) of NanoRepro is 2025 11.40 M EUR. Enterprise Value (EV) of NanoRepro was 2024 10.06 M EUR. It decreases by 13.27% higher compared to the previous year.

The NanoRepro Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
17.39 M EUR
Jan 1, 2019
18.62 M EUR
Jan 1, 2020
19.35 M EUR
Jan 1, 2021
-8.71 M EUR
Jan 1, 2022
-12.10 M EUR
Jan 1, 2023
-1.46 M EUR
Jan 1, 2024
10.06 M EUR
Jan 1, 2025
11.40 M EUR
The NanoRepro Enterprise Value history
YEAREnterprise ValueYoY
11.40 MEUR+13.27%
10.06 MEUR-789.78%
-1.46 MEUR-87.94%
-12.10 MEUR+38.96%
-8.71 MEUR-144.99%
19.35 MEUR+3.90%
18.62 MEUR+7.07%
17.39 MEUR-7.34%
18.77 MEUR-0.10%
18.79 MEUR-0.83%
18.95 MEUR-1.14%
19.16 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NanoRepro Stock analysis

What does NanoRepro do? The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoRepro stock

Enterprise Value (EV) of NanoRepro is 11.40 M EUR in 2025.

Enterprise Value (EV) of NanoRepro changed from 10.06 M EUR to 11.40 M EUR, representing a 13.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) NanoRepro since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s EUR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' EUR varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s NanoRepro with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — NanoRepro

All Key Metrics — NanoRepro